TOKYO -- Fujifilm Holdings will spend 90 billion yen ($813 million) on biologics manufacturing unit Fujifilm Diosynth Biotechnologies, the company announced Tuesday, accelerating its push into a field that is experiencing surging demand amid the coronavirus pandemic.
Producing biologic treatments, which involve steps like making cell cultures and genetic manipulation, requires expensive equipment and advanced technology, leading more drugmakers to contract out their development and production to companies like Fujifilm Diosynth, a joint venture with trading house Mitsubishi Corp. The latest announcement brings Fujifilm's total investment in the sector to $5.5 billion.
